What is HC Wainwright’s Forecast for Genmab A/S Q1 Earnings?

Genmab A/S Sponsored ADR (NASDAQ:GMAB) – Analysts at HC Wainwright lowered their Q1 2026 earnings estimates for Genmab A/S in a research report issued to clients and investors on Monday, November 10th. HC Wainwright analyst R. Selvaraju now expects that the company will earn $0.34 per share for the quarter, down from their previous forecast of $0.36. HC Wainwright has a “Buy” rating and a $41.00 price objective on the stock. The consensus estimate for Genmab A/S’s current full-year earnings is $1.45 per share.

Other analysts have also recently issued reports about the stock. Guggenheim upgraded shares of Genmab A/S from a “neutral” rating to a “buy” rating and set a $43.00 price objective for the company in a research note on Tuesday, September 23rd. Truist Financial reissued a “buy” rating and set a $48.00 target price (down previously from $49.00) on shares of Genmab A/S in a research report on Thursday, November 6th. Wall Street Zen cut shares of Genmab A/S from a “buy” rating to a “hold” rating in a report on Saturday, November 8th. Zacks Research lowered Genmab A/S from a “strong-buy” rating to a “hold” rating in a research note on Friday, October 31st. Finally, Johnson Rice reissued a “buy” rating on shares of Genmab A/S in a research report on Monday, October 27th. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Genmab A/S currently has a consensus rating of “Moderate Buy” and a consensus target price of $39.75.

Genmab A/S Stock Down 0.8%

Shares of Genmab A/S stock opened at $30.24 on Wednesday. Genmab A/S has a 12-month low of $17.24 and a 12-month high of $33.65. The stock has a 50 day moving average price of $29.90 and a two-hundred day moving average price of $24.69. The stock has a market capitalization of $19.42 billion, a P/E ratio of 12.87, a PEG ratio of 1.58 and a beta of 0.96.

Genmab A/S (NASDAQ:GMAB) last released its quarterly earnings results on Thursday, November 6th. The company reported $0.65 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.48 by $0.17. Genmab A/S had a return on equity of 23.98% and a net margin of 41.36%.The company had revenue of $1.02 billion during the quarter, compared to the consensus estimate of $975.40 million. Genmab A/S has set its FY 2025 guidance at EPS.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the stock. Envestnet Asset Management Inc. increased its stake in Genmab A/S by 1.7% during the first quarter. Envestnet Asset Management Inc. now owns 736,326 shares of the company’s stock valued at $14,417,000 after acquiring an additional 12,545 shares during the period. DDD Partners LLC grew its holdings in shares of Genmab A/S by 165.9% during the 1st quarter. DDD Partners LLC now owns 601,050 shares of the company’s stock worth $11,769,000 after purchasing an additional 374,976 shares in the last quarter. Grandfield & Dodd LLC grew its holdings in shares of Genmab A/S by 18.3% during the 1st quarter. Grandfield & Dodd LLC now owns 39,893 shares of the company’s stock worth $781,000 after purchasing an additional 6,160 shares in the last quarter. Wealth Alliance LLC bought a new stake in shares of Genmab A/S during the first quarter valued at approximately $277,000. Finally, Gallacher Capital Management LLC raised its stake in shares of Genmab A/S by 6.8% in the first quarter. Gallacher Capital Management LLC now owns 14,346 shares of the company’s stock valued at $281,000 after purchasing an additional 915 shares in the last quarter. Institutional investors and hedge funds own 7.07% of the company’s stock.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.